You are here: All Products  > Kelun-Biotech’s Lead ADC Meets Endpoint in Phase III Triple Negative Breast Cancer Trial

Kelun-Biotech’s Lead ADC Meets Endpoint in Phase III Triple Negative Breast Cancer Trial

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products